Skip to main content
NeopharmCO.,LTD. logo

NeopharmCO.,LTD. — Investor Relations & Filings

Ticker · 092730 ISIN · KR7092730001 KO Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2023-03-27 Director's Dealing
Country KR South Korea
Listing KO 092730

About NeopharmCO.,LTD.

https://neopharm.co.kr

Neopharm is a science-based company specializing in the development, manufacturing, and sale of dermatological skincare and cosmetic products. A pioneer in skin barrier research, the company focuses on restoring skin homeostasis. Its core innovation is the proprietary Multi-Lamellar Emulsion (MLE) technology, which mimics the natural lipid structure of the skin to repair and strengthen its protective functions. The company's primary product lines, including the flagship brand Atopalm, are specifically formulated for sensitive, dry, and compromised skin. These non-steroid solutions are grounded in dermatological science to address various skin concerns.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of a specific executive (Kim Yoon) of Neopharm due to their resignation. This type of filing is a standard regulatory requirement for insider trading or changes in ownership by company directors/executives, which corresponds to the 'Director's Dealing' category.
2023-03-27 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides the official outcomes of the shareholder meeting held on 2023-03-23, including the approval of financial statements, dividend resolutions, and board appointments. This aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2023-03-23 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the fiscal year 2022 (Jan 1, 2022 to Dec 31, 2022) for NeoPharm Co., Ltd. It contains comprehensive financial data, management discussion, business overview, and governance details. In the context of Korean corporate filings, the 'Business Report' (사업보고서) is the equivalent of the US 10-K annual report. It is not an announcement or a summary, but the full annual report itself. FY 2022
2023-03-15 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Neopharm. It provides a summary of the audit opinion (unqualified/proper), key financial data (assets, liabilities, equity, revenue, profit), and auditor information. While it contains financial data, it is a standard regulatory disclosure announcement regarding the receipt and submission of the audit report to the exchange, rather than the full annual report (10-K) or a standalone audit report (AR). In the context of Korean regulatory filings (DART), this is a specific disclosure announcement of the audit report submission. FY 2022
2023-03-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership (disposal of shares), and the purpose of holding (influencing management) by Templeton Asset Management, Ltd. in the company Neopharm. This falls under the category of Major Shareholding Notification (MRQ) as it tracks significant ownership changes and regulatory reporting of shareholding thresholds.
2023-03-08 Korean
주주총회소집공고
AGM Information Classification · 99% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Neopharm's 23rd Annual General Meeting. It contains the meeting agenda, voting procedures (including electronic voting), and detailed financial information (financial statements, audit reports, and management reports) required to be provided to shareholders under Korean commercial law for the purpose of the meeting. While it contains financial data, it is not an Annual Report (10-K) or an Interim Report (IR) itself, but rather the proxy/notice material for the AGM. Therefore, it is classified as Proxy Solicitation & Information Statement.
2023-03-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.